Open Label Trial to Assess Iressa in Prostate Cancer Patients
NCT ID: NCT00635856
Last Updated: 2009-04-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
100 participants
INTERVENTIONAL
2001-05-31
2003-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Trial of Iressa in Prostate Cancer Patients
NCT00265070
ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
NCT00025116
Gefitinib in the Treatment of the First Relapse of Prostate Cancer Beyond Prostatectomy or Radiotherapy
NCT00241475
Combination Casodex® and Iressa™ in Locally Advanced Prostate Cancer
NCT00319787
Safety Study to Explore Combination of Gefitinib (ZD1839, Iressa) and Radiotherapy in Non-Metastatic Prostate Cancer
NCT00239291
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Gefitinib
Iressa
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* no evidence of metastasis
* Age 18 or older
Exclusion Criteria
* Radiotherapy completed within 28 days of starting the study
* Incomplete healing from prior cancer or other major surgery
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AstraZeneca
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1839US/0040
Identifier Type: -
Identifier Source: org_study_id
NCT00033579
Identifier Type: -
Identifier Source: nct_alias
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.